NASDAQ: FEAM5e Advanced Materials Inc Stock
$0.47-0.02 (-4.08%)
Updated Jan 17, 2025
FEAM Price
$0.47
Fair Value Price
N/A
Market Cap
$32.58M
52 Week Low
$0.38
52 Week High
$2.48
P/E
-0.42x
P/B
15.56x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$65.50M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
39.96
Operating Cash Flow
-$26M
Beta
1.08
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FEAM Overview
5E Advanced Materials Inc. explores for and develops borates and lithium deposits in Australia and the U.S. Formerly known as American Pacific Borates Ltd., the company was incorporated in 2016 and is headquartered in Houston, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FEAM's potential to beat the market
- FEAM doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Specialty Chemical
Industry Rating
B
FEAM
RankedUnranked of 53
RankedUnranked of 53
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.53 | A | |
| $495.59 | A | |
| $42.61 | A |
Be the first to know about important FEAM news, forecast changes, insider trades & much more!
FEAM News
Overview
Due Diligence Score
–
Industry Average (38)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FEAM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FEAM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FEAM is poor value based on its book value relative to its share price (15.56x), compared to the US Specialty Chemicals industry average (3.29x)
P/B vs Industry Valuation
FEAM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FEAM due diligence checks available for Premium users.
Valuation
FEAM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.42x
Industry
29.47x
Market
30.45x
FEAM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
15.56x
Industry
3.29x
FEAM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FEAM's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.9M
Profit Margin
0%
FEAM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$85.8M
Liabilities
$83.7M
Debt to equity
39.96
FEAM's short-term assets ($8.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FEAM's long-term liabilities ($76.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FEAM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.4M
Investing
-$400.0k
Financing
$8.7M
FEAM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FEAM vs Specialty Chemical Stocks
5e Advanced Materials Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.